NEU 2.81% $18.65 neuren pharmaceuticals limited

Ann: Annual Report to shareholders, page-18

  1. 934 Posts.
    lightbulb Created with Sketch. 154
    Silent,
    Just to clarify Neuren received Orphan Drug status but was denied Breakthrough therapy designation by the FDA. From my very limited knowledge these are two very different FDA approvals.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.